Site Map
Home
About Us
- About Us Overview
- Historical Timeline
- Executive Team
- Board of Directors
- Corporate Responsibility
- Corporate Values
- Contact Us
Products
Development
- Development Overview
- Clinical Pipeline
- Nexavar (sorafenib)
-
Carfilzomib
- Multiple Myeloma
- Solid Tumors
- ONX 0801
- ONX 0803 and ONX 0805
- ONX 0912 (formerly PR-047) and ONX 0914 (formerly PR-957)
- Cell Cycle Kinase Inhibitor
Investors
- Investors Overview
- Financial Information
- Stock Information
- Analyst Coverage
- Event Calendar
- Annual Report
- Proxy Materials
- SEC Filings
- Corporate Governance
- Information Request